We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 23, 2022

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction

JAMA Cardiology

 

Additional Info

JAMA Cardiology
Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
JAMA Cardiol 2022 Oct 03;[EPub Ahead of Print], AS Desai, PS Jhund, BL Claggett, M Vaduganathan, ZM Miao, T Kondo, E Barkoudah, A Brahimi, E Connolly, P Finn, NN Lang, FR Mc Causland, M McGrath, MC Petrie, JJV McMurray, SD Solomon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading